

PARIS FASHION WEEK

Dior, still marching to the same tune

Maria Grazia Chiuri is sticking to her empowerment narrative at Dior. But is it starting to look a little old?

FASHION

Jo Ellison



Maria Grazia Chiuri showed her AW18 collection yesterday, her first under the house's new chief executive Pietro Baccari, an Italian who joined the group from the LVMH-owned Fendi. He has big shoes to fill.

Baccari now assumes the role held by Sidney Toledano, who was appointed in 1998 and has led the culture of Dior for nearly 20 years. Toledano launched the bestselling Lady Dior handbag, and steered the house through the crisis of John Galliano's nervous breakdown. He oversaw the short tenure of Raf Simons and the arrival of Chiuri, "the first female creative director of womenswear" at the house. Now, he has gone to oversee the group's "other labels" — including Givenchy, Loewe and the Hedi Slimane-designed Céline. Baccari arrives with the aura of a new dawn at Dior.

No pressure there then. Christian Dior is not allowed to fail. The crown jewel of the LVMH portfolio, Bernard Arnault, the group's chairman and chief executive, purchased it for one franc in 1984 and has since transformed it into a near €5bn brand. Last summer, Groupe Arnault paid €12.1bn for the minority stake in Christian Dior it does not already own. The deal increased the family stake in LVMH to about 46 per cent, and helped contribute to the group's "record" year (in January it reported sales of €42.6bn).

Dior's divisions — which include, among other things, beauty, leather goods and ready-to-wear — obscure the specifics of its revenues. Hence any thorough analysis of Chiuri's success with the womenswear is hard to ascertain. Certainly, the designer has succeeded in driving the category growth. She's launched sticky new "It" accessories. She's introduced wearable clothes with a real-life purpose and designs with a diverse range of clients in mind. She's also pushed a feminist agenda in keeping with the times: her position should be unassailable. But her collections have often failed to ignite critical ardour. Some say her Dior is a bore.

For AW18 the women's agenda was placed once again at the fore. A montage of empowering slogans, magazine covers and power women



Getty Images, Catwalking



decorated the show space of the Rodin museum, and the models marched in the familiar threads of 1960s libertarianism. The first one out wore a sweater emblazoned with the words "c'est non, non, non et non", with a black kilt and heavy black boots. The show had been inspired by a quote of Diana Vreeland's: "The Sixties were about personalities. It was the first time when mannequins became personalities. It was a time of great goals, an inventive time... And these girls invented

themselves." Hence, there were denims and CND knits; tailored jackets in a theme of tartan; multiple "ethnic" embroideries and velvety, patchouli-infused patchworks.

The accessories were especially strong: many of the models wore suede hooded caps (part of a "balaclava" trend that has been emerging all season), and following her success with the kitten heel and sneaker, Chiuri had alighted on a new hit shoe — this time a patchworked hybrid cowboy boot, and

a hippie-style studded clog. Could we feel Baccari's influence already? Fendi's recent success has been driven by its focus on customisation and accessory extras, and some of those hallmarks could be found here: the bold, embroidered straps in particular looked like they might become part of an interchangeable offering. And there was a new belt buckle — an oversized "D".

Otherwise it was a show for the everywoman — with wide-legged suits, archive prints, biker leathers and sheer organza dresses worn with branded lingerie. That the first woman designer at Dior has alighted on an all-encompassing feminist narrative to underpin her tenure is no wonder. It's smart, it's relevant and it sidesteps too

Chiuri's collections have often failed to ignite critical ardour. Some say her Dior is a bore

much scrutiny. This show's cheerful palette and right-on motivation recalled the kind of Woodstock-era optimism for which there will always be a hearty nostalgia. But do I really want to wear the hippie uniform once worn by my mother — even when it's immaculately made? On the Dior catwalk, the patchworks, the tailoring and the embroideries were impeccable, the clothes were arresting, and the range nice and broad. But with so much 1960s-wear on view there were times when the collection smacked of fancy dress — or a film set.

Vreeland's point was that the most inspiring aspect of the 1960s was in its invention. How women used clothes to express their true selves. There was little invention here. Chiuri's fidelity, while charming, felt a little bit too literal. In 2018, she could have moved it more along.

Sole woman: Nike embraces female footwear

Nike is rethinking how it sells trainers to women — and that means unisex sizing and curated spaces.

By Carola Long

Many sneaker-loving women will know the frustration of spotting the perfect pair of trainers only to find out that, yet again, they only come in men's sizes. The women's sections of sports shops are often dominated by overtly girly details, from pink or gold trims to snakeskin inserts. Not everyone wants to do the tennis court or commute in sugary sneakers.

Now, Nike has taken this realisation and made it a central part of its new female-centric retail concept, Nike Unlaced. It will take the form of an online destination on the Nike website, launching March 27, as well as a physical, curated area in key Nike Stores from the summer. Amy Montagne, global vice-president and general manager of Nike Women, says: "One of the most important things we will be doing is giving women access to and choice of product like never before. We are removing barriers with unisex sizing throughout the lines — and that includes high-heat [the most covetable] products like the new Virgil Abloh x [Air] Jordan 1 — which is really important for women."

Capitalising on women's increasing appetite for cutting-edge sportswear makes sense for the brand. Although at the end of the last financial year the women's sportswear business at Nike was worth less than the men's, at \$6.6bn compared with \$16bn, sales of women's shoes and apparel at Nike have been growing faster than men's for several years, and they expect that trend to con-

tinue. The Unlaced concept was initially trialled in Nike retail stores in London and the brand saw strong double-digit sales increases compared with the same period the previous year.

Julie Igarashi, vice-president and creative director of Nike Women, picks up on the appetite for unisex sizing: "People are multidimensional today, especially the millennial generation; we want to express our style in a variety of different ways." And she believes that a passion for sneakers isn't restricted to men, as is often the stereotype. She reports that when Nike hosted a pre-launch of the 1 Reimagined collection, footwear created by a 14-strong female design collective, at New York Fashion Week, "we had women queuing up to buy it — there is definitely a rise in female sneakerheads." As part of Unlaced, consumers will have access to personal stylists, and Nike has also enlisted global fashion experts and influencers to curate their women's products and inject a fashion sensibility




Nike Women's Amy Montagne

that reflects their particular city.

The rise of athleisure-wearing sportswear-inspired garments as everyday clothing — and the boom in gym-going — has fuelled this growth. Montagne says: "One of the things we have seen over the last few years is that women truly are the leaders of the sport and fitness lifestyle. We see a big shift in how women are living their lives, and fueling the overall industry, and this has pushed us into some new zones." Recent high-profile launches for women at Nike have included the campaign for their new "Pro Hijab" modest headwear and a plus-size sportswear collection.

There will be a continued crossover between fashion and function. Montagne says: "We have been listening to female consumers and athletes for 40 years and we have always been rooted in performance and innovation. We have also learned that it's really important to deliver on the fact that for women in particular there is no performance without style."

And which styles are seeing the most demand? Igarashi cites the Cortez, which was Nike's first shoe for women, introduced in 1972 and recently reinvented. The Monarch is one of the top-selling styles ever at Nike, but it's not everyone's idea of a hip shoe. It's a clumpy white normcore running trainer of the kind American dads who wouldn't know their Balenciaga from their Balmain might wear to the mall, but over the past six months Igarashi reports that it has had a major revival as part of an ironic dad-fashion movement Nike is dubbing "Mr Nike". In a true rejection of preconceived ideas about what women like in their shoes, the stylist Julia Sarr-Jamois will be curating a whole Mr Nike selection for Nike Unlaced, available online. Igarashi says: "This launch is really going to put some gas under sneaker culture."



LOUIS ROEDERER
À LA RECHERCHE DE L'ŒUVRE

ARTS

Flórez blazes his way to paradise

OPERA

Orphée et Eurydice
La Scala, Milan
★★★★☆

James Imam

In La Scala's production of *Orphée et Eurydice*, it is the orchestra that makes the journey into the underworld. Placing the musicians centre-stage, on a platform that rises and falls, hints at what the directors see as the essence of Gluck's opera. The Orpheus myth is not simply a story about a Thracian poet who saves his wife from Hades. It is an ode to music itself.

La Scala is presenting the work in its 1774 Paris version for the first time. If the opening performance never quite got into its stride, it is difficult to blame the production. Certainly, this joint effort from director John Fulljames and choreographer Hofesh Shechter, on loan from the Royal Opera House, invests Conor Murphy's beautifully ethereal sets with few ideas apart from the rising platform. But straightforward storytelling was central to Gluck's reformist agenda, and, by funnelling the characters' emotions through a score of striking simplicity, the composer put the dramatic emphasis on the music.

The weak point of this performance was the playing. Conductor Michele Mariotti can work magic when given sparkling bel canto or yearning Romantic melodies to craft. But here he sounded straitjacketed by the music's classical proportion, providing pristine surface layers while never making the passion burn beneath.

One musician who did get it right was Juan Diego Flórez. The tenor does not possess the light haute-contre voice for which the title role was re-scored, but

Majestic: Juan Diego Flórez and Christiane Karg in 'Orphée et Eurydice'. Right: Bill Milner and Sheila Hancock in 'Harold and Maude'

Brescia/Amisano; Darren Bell



his blazing tone streamed majestically through Gluck's lines, and the fearsome bravura aria was thrilling. Flórez combined authentic vehemence with a sense of steadfast self-possession; he cut the archetypal, if sometimes broodingly Romantic, Gluckian Orpheus, mastering his emotions with music in a personalised journey to paradise.

Fatma Said was a puckish Amour, and Christiane Karg's Eurydice steered clear of irascibility to lure Orphée with singing of utmost grace. La Scala's superlative chorus sculpted its contributions idiomatically and with sensitivity. But limp playing from the orchestra meant this performance remained firmly earthbound.

To March 17, teatroallascala.org

THEATRE

Harold and Maude

Charing Cross Theatre, London
★★★★☆

Ian Shuttleworth

It has grown from obscurity to cult respect, but Hal Ashby's 1971 film is still well at the obscure end of cultishness. It is one of the most whimsical movies of its period, telling of a discontented 18-year-old rich boy falling in love with a relentlessly rebellious yet charming 79-year-old woman. Director of this stage version Thom Southerland has pulled a few of the story's teeth and frankly copped out once or twice, but

it is impressive how much of Colin Higgins' unsettlingly chucklesome screenplay remains.

This is, I suspect, largely because the stage adaptation (from 1974) is by Higgins himself. It is adroit at folding the variety of film locations on to a single stage, at not assigning too much extra dialogue to fill in the visual gaps (in particular, I heaved a huge sigh of relief when the reason for Maude's indefatigable joie de vivre was conveyed with an elliptical phrase or two rather than spelt crashingly out) and at allowing the tale to take its own shape.

Bill Milner keeps a tight rein on Harold, which is sometimes unhelpful in his scenes with Maude but always pays off when interacting with his controlling mother (an excellent Rebecca Caine) and engaging in his hobby of painstakingly staged mock suicides. Sheila Hancock — now 85 herself — could not be bettered as Maude: at once impassioned and mischievous, she makes every one of her "misdeeds" credible.

Higgins and/or Southerland do well to recognise the importance of music: the film resonates with the songs of Cat Stevens. Here, the supporting actors play Michael Bruce's score on whatever instruments they can handle: Joanna Hickman, as well as portraying a clutch of excruciating computer dates for Harold, even provides a cello rendition of the other end of telephone conversations. One of the two serious mis-steps is the dippy song that brings Harold and Maude together; the production would have done much better simply to acquire the rights to perform Stevens' "If You Want to Sing Out, Sing Out". This further weakens a stage ending which is already tipping into sentiment. Nevertheless, it succeeds overall both in itself and as a nudge to seek out the film.

To March 31, charingcrosstheatre.co.uk



THEATRE

Trust

Gate Theatre, London
★★★★☆

Sarah Hemming

"Let's just leave things the way they are," is a refrain that runs through Falk Richter's caustic, playful 2009 piece (translated from the German here by Maja Zade). "It's taken us so long to get here / It was so so / Exhausting." It's the recurring conclusion of a warring couple, whose tottering relationship repeatedly breaks down and reassembles before us. It's also the reasoning of an anonymous monologue, voiced here by director Jude Christian, that queries whether the advanced capitalist system as we know it faces imminent collapse. "What would we do with this information?" she asks. "Let's just leave things the way they are."

Richter's text links these two scenarios — the personal and the socio-economic — to examine a deep-rooted apathy: faced with the unknown, it suggests, we tend to stick with what we know and try to prop it up even if we don't trust it. His script is a collage of monologues and dialogues with no identified characters or speakers.

Christian stages it as something between an art installation, a cabaret and a social media website, endlessly refreshed with unrelated and distracting information. Each change of scene is prefaced with a caption; screens drop from the ceiling and play soothing films of a beach or of animals being cute; a woman tips a packet of breakfast cereal over her partner. Meanwhile there are invitations to the audience to participate — have a drink, bark like a dog, pop on this flight blanket and eye-mask.

Christian's production is inventive and delivered with a nice, tongue-in-cheek sense of humour. Pia Laborde Noguez and Zephryn Taitte as the bewildered couple squabble and make up and roll about like puppies, while Christian herself steps in to deliver props or speeches. But as time rolls on, the piece starts to feel laboured and gratingly repetitive. The final section, in which the three performers conduct a lengthy yoga session to a voiceover on a loop about the perpetuation of the system, may demonstrate our insulated self-absorption, but it feels interminable.

To March 17, gatetheatre.co.uk

Intense drama of pride and prejudice

THEATRE

An Ordinary Muslim

New York Theatre Workshop
★★★★☆

Max McGuinness

The titular "ordinary Muslim" of Hammaad Chaudry's new play is Azeem Bhatti, a thirtysomething Londoner and son of Pakistani immigrants. Azeem works in a bank, where he's all set to be appointed manager, and seems more or less happily married. Like his father Akeel, he has contempt for the "Jamaat", a cultish movement that controls the local mosque. He also disparages his wife Saima for wearing a headscarf to work lest it cost her a promotion. And though officially teetotal, he struggles to avoid the temptation of a pint of Guinness.

But Azeem is no tradition-bashing secularist. He attends Friday prayers and feels ill at ease in Britain, where, as he sarcastically remarks, "a good Muslim is an invisible Muslim". And his country's colonial history and present-day racism rankle so bitterly that he tells a white friend: "When I see a Muslim go after you fuckers... I get it." As Azeem's life falls apart, there's even a faint suggestion that he might be the kind of angry, dislocated young man who would go to fight in Syria.

THEATRE

Those contradictions make Azeem an unusually rich and complex protagonist. And Sanjit De Silva plays the role with a sympathetic blend of pride and intelligence overlain with mounting frustration. Purva Bedi similarly evokes the swirl of competing desires and loyalties inhabiting Saima (even if the motivations behind her increasing religiosity are never fully explored). And Ranjit Chowdhry's Akeel is an abusive patriarch who nonetheless cuts a dignified figure, while Rita Wolf adds a dash of grit to the part of his subservient wife Malika.

Under Jo Bonney's fluid direction, their domestic and professional conflicts

unfold in an intense-yet-understated naturalistic style reminiscent of Arthur Miller. Underlying that formal achievement is Chaudry's dialogue, which has a spontaneous, improvised feel that sounds consistently authentic.

We might have heard more from Azeem's sister Javeria (a self-possessed Angel Desai), who seems to balance the demands of faith and modernity with more success than the other Bhattis. But this debut play nonetheless skillfully dramatises one family's unhappy struggle to be ordinary while preserving their distinctness.

To March 11, nytwo.org



From left, Purva Bedi, Rita Wolf, Ranjit Chowdhry and Sanjit De Silva in 'An Ordinary Muslim'
Suzi Sadler

CLASSICAL MUSIC

**Leipzig Gewandhausorchester/
Nelsons**

Leipzig Gewandhaus
★★★★☆

Shirley Apthorp

After two long years without a musical chief, Leipzig's Gewandhausorchester has appointed its 21st Gewandhauskapellmeister. Andris Nelsons follows such distinguished antecedents as Felix Mendelssohn Bartholdy, Wilhelm Furtwängler, Bruno Walter and Kurt Masur — and took up his post last week with both modesty and an eye to the future.

In a programme that combined Mendelssohn with a brand new work and a 20th-century classic, Nelsons made a declaration of intent to move his orchestra beyond the more conservative focus of his predecessor, Riccardo Chailly. But the evening was also striking for its understatement.

Leipzig composer Steffen Schleiermacher's *Relief für Orchester* is written for the same orchestration as Alban Berg's violin concerto. It manages to be both unassuming and impressive, describing the altitude profile of a mountain hike, or the raised ridges on a work of art, in the course of an engaging trot through most of the orchestral sections. After gently showing the orchestra's many strengths, *Relief* plunges us down to the depths of a double bass abyss, the perfect launching pad for the delicacy with which Berg reaches for the heavens in the first notes of his concerto.

And Latvian violinist Baiba Skride takes a celestial approach to Berg's work, opting for ethereal purity rather than gritty humanity. Manon Gropius, daughter of Alma Mahler and Walter Gropius, died of polio at the age of 18; the work is dedicated to her. But Berg wrote it while he was working on his opera *Lulu*, and plenty of that sinuous, ambivalent figure can be heard in the concerto. Skride left the anguish to Nelsons and his orchestra, floating

above it all with glassy detachment. In the final movement's Bach chorale, given flawless intonation by the woodwind, the link to Leipzig became suddenly, movingly evident. Nelsons took the final phrases upwards with a physical gesture to the heavens which he held for tense seconds of silence, emphasising the work's sense of the transcendent.

Mendelssohn's *Scottish* Third Symphony formed the concert's second half, a solid piece of Leipzig tradition to which Nelsons brought a lush romanticism sometimes heavier than the fleetness of which the orchestra is capable. Perhaps the most intriguing aspect of this fledgling relationship is the lack of arrogance on either side. Sometimes the orchestra does not play exactly as Nelsons directs; on the other hand, sometimes the players give him more details and refinement than he has commanded. There is room to grow here, and a sense of give and take; the new partnership brims with artistic promise.

gewandhausorchester.de

46th 香港藝術節
HK ARTS FESTIVAL
23.2 - 24.3.2018

SPECIAL THANKS TO
THE FESTIVAL FINALE SPONSOR

ICBC 工银亚洲

ESTONIAN NATIONAL
SYMPHONY ORCHESTRA AND
ESTONIAN NATIONAL MALE CHOIR

LEIF SEGERSTAM CONDUCTOR

24 MAR 2018 FESTIVAL FINALE
SAT, 8:00 PM
CONCERT HALL, HK CULTURAL CENTRE



What's real to me
真·我角度

MORE ON
hk.artsfestival.org

香港藝術節的資助來自
The Hong Kong Arts Festival is made possible with the funding support of
香港賽馬會慈善基金
The Hong Kong Jockey Club Charities Trust
康樂及文化事務署
Leisure and Cultural Services Department

SUPPORT THE FESTIVAL WITH A DONATION: go.hkaf.org/8qcrs

FT BIG READ. ITALY'S ELECTION

As Italians go to the polls on Sunday, many are in an anti-establishment mood. While big business wants to continue the reforms of the centre-left government, some voters feel left out of the economic rebound.

By James Politi

Weak recovery fuels discord

As Italy prepares to go to the polls on Sunday for an election that is the latest test of Europe's populist insurgency, two businesses on either side of Turin in the north-west of the country are experiencing vastly different fortunes.

To the west of the Italian city that is the home to Fiat cars, Gianfranco Carbonato's company, Prima Industrie — a maker of laser metal-cutting machinery with plants in four countries — is doing well, with sales rising 15 per cent last year and early figures for 2018 looking encouraging. The 72-year-old owner worries that the looming general election could jeopardise the country's painstaking and fragile economic progress over the past few years.

"The hope is that politics doesn't damage things too much," says Mr Carbonato, who also sits on the board of Intesa Sanpaolo, Italy's largest bank. "Politics needs to keep working to make this country more normal, not invent God-knows-what-kind of solutions. That's the danger."

Yet such satisfaction with the current outlook is not felt by many of the country's smaller businesses — or indeed, according to polls, by a lot of voters. The stronger headline numbers and improving exports have yet to feed through to sentiment further down the economic

'Whether you have a centre-right coalition or a grand coalition, the government looks set to blow through the budget deficit'

chain, which is encouraging support for more radical change. To the east of Turin in Chieri, on the edge of a town where Whirlpool, the US appliance maker, recently announced plans to lay off 500 workers, patience has run thin and the mood is bitter.

"The government says there's a recovery? It's all baloney — no more, no less. Only misery is recovering," says Piero Sciarretta, the 49-year-old owner of La Bottega del Colore, a paint and varnish store near the local railway station which he runs with his wife. "There's no money, there's truly no money."

Mr Carbonato's fear of a looming shake-up in the eurozone's third-largest economy — at a time when the currency bloc is gearing up to pursue deeper integration — is common among business leaders. Globally competitive companies like Prima Industrie that survived the country's sovereign debt crisis, triple-dip recession and banking woes have helped pull the economy out of the morass through a surge in exports and investment. Many of them look favourably on the status quo in Rome, led by prime minister Paolo Gentiloni of the centre-left Democratic party.

Though well below the eurozone average of 2.4 per cent, the country's gross domestic product grew at a rate of 1.5 per cent in 2017, its fastest since 2010, and is expected to maintain that momentum this year, according to the European Commission. Italian shares have been among the best performers in Europe; and the country's 10-year bond yield, a key measure of its borrowing costs and investor confidence in its fiscal sustainability, has remained low, hovering around 2 per cent.

Weak link in Europe

Among big businesses in Italy, there are growing jitters that all this could be lost in the event that populist parties — the anti-establishment Five Star Movement and the far-right Eurosceptic Northern League, in particular — gain ground in Sunday's vote.

"There's no doubt that the elections could deliver a confused picture, and with a few wrong steps our country would quickly become the weak link in the world, with systemic consequences given the dimension of our public debt and Italy's weight in the eurozone," was the stark warning delivered by Confindustria, Italy's largest business lobby, in a report released this month.

The latest polls, published on February 16 before a 15-day blackout, suggest a wide range of outcomes. The pro-EU ruling Democrats are likely to lose many seats — and almost certainly its ability to govern the country on its own with a few reliable allies. One result could be a grand coalition, or national unity government, of centrist political forces including both the Democratic party and Silvio Berlusconi, the 81-year-old



Top, from left: Matteo Renzi of the Democratic party; Forza Italia's Silvio Berlusconi; Five Star's Beppe Grillo; and the Northern League's Matteo Salvini — FT montage

former prime minister and leader of the Forza Italia party. He cannot be premier himself due to a ban from public office related to a tax fraud conviction.

Another possibility could be an outright victory for a centre-right coalition that not only includes Mr Berlusconi's party but also the Northern League and Brothers of Italy, another far-right Eurosceptic party, with the strongest of the three choosing the next prime minister. The anti-establishment Five Star Movement could also still emerge as the biggest party. And even if it cannot find enough allies to form a government, it will probably hold greater sway over Italian political life than it has so far.

What is certain is that the Democratic party has struggled to persuade many Italians that they are benefiting from a broadening recovery. In fact big chunks of the electorate believe business leaders and politicians who speak of a rebound are operating in a parallel universe. While unemployment fell to 10.8 per cent in December 2017 from a post-crisis peak of 13 per cent in late 2014, it remains well above its pre-crisis rate which was below 7 per cent.

Household purchasing power has also regained some ground, but has still not filled the hole created by the financial crisis. Poverty — which is most prevalent in southern regions suffering from few job opportunities, poor infrastructure and demographic flight — has been flat in recent years.

In such an environment of widespread popular discontent, opposition parties have found it easy to persuade voters that this is the time for a change — and even radical change.

While the Democrats are campaigning on a message of competence and stability, promoting incremental changes to existing policies, both the centre-right and Five Star say it is time for a major fiscal expansion, even at the cost of spooking the markets about Italy's fiscal stance. While Five Star and the Northern League have toned down their rhetoric on an Italian exit from the euro,

Mr Berlusconi wants to introduce a costly flat tax and increase pensions and Five Star is promoting a guaranteed minimum income for the poorest Italians.

Each of these proposals, if implemented, would substantially increase Italy's budget deficit, possibly leading to clashes with Brussels and a sell-off in debt. "In the medium term, whether you have a centre-right coalition or a grand coalition, the government looks set to blow out the budget deficit," says Megan Greene, chief economist at Manulife in Boston.

Indeed, in a speech in early February, Ignazio Visco, the Bank of Italy governor, tried to encourage politicians of all stripes to rein in their fiscal promises. "This is about balanced development," he warned. "An increase in the deficit cannot replace reforms and risks being counterproductive. The problem of debt cannot be avoided."

To some economists, these concerns are exaggerated. "I actually think that the best way to ensure fiscal sustainability is to make sure people want to live in a country, want to pay taxes in a country, want to have babies in a country," says Raffaella Tenconi, the founder of Ada Economics in London. "Further austerity is counterproductive, and a certain ambition in the magnitude of fiscal adjustment is highly desirable."

To others, however, the post-crisis window for fiscal stimulus has passed because the risks of further indebtedness would outweigh the benefits. "When our growth was zero, there was a serious lack of demand and you needed to increase deficits," says Francesco Giavazzi, at Bocconi University in Milan. "But we are now at a different point. The issue is how to raise potential output, it's a very different environment."

Trying to compete

The potential disruption to Italian economic policy is not confined to the fiscal realm, however. Since 2011, after Mr Berlusconi left office, the country

embarked on a round of economic reforms which could now be stalled or overturned, including a 2012 increase in the age of retirement and a labour market overhaul launched in 2015 that made it easier to fire workers — and to hire them — by establishing a less rigid form of permanent contract.

Both policies were unpopular with voters and have been lambasted almost incessantly by both Five Star and the

Northern League and Five Star have opposed the deals and, along with Mr Berlusconi, have generally been more resistant to foreign takeovers or investment in the country.

Matteo Salvini, the leader of the Northern League, has openly embraced US president Donald Trump's push for more tariffs. "If Italians will choose me as prime minister I will [impose tariffs] like Trump. I will defend Italian workers and entrepreneurs even if it means putting up tariffs to protect the 'made in Italy' brand," he says.

Carlo Calenda, Italy's economic development minister, says the idea is "dumb and unfeasible" because only the EU could set tariffs, but the broader lesson was that Italy's trade surplus meant that its own economy would suffer most from an escalation in protectionism.

One area in which the centre-left government struggled badly in 2015 and 2016 was its handling of a banking crisis driven by high non-performing loan rates at a number of large and regional institutions including Monte dei Paschi di Siena, the world's oldest bank, two regional banks in Veneto and several others in central Italy. NPL rates have however come down substantially since then, and a series of multibillion-dollar rescues managed to stabilise the Italian banking system, for the time being at least.

"I would argue that the big problems in the Italian system are solved by now, and the rest of the system is stable and we have seen positive development on the NPL side," says Silvia Merler, an analyst at Bruegel, the Brussels-based think-tank. "One interesting question is whether there may be issues in the pool of smaller banks, which are not under the ECB's oversight, but even if that were the case we would be talking of small numbers."

But for many in Italy, there always seems to be another crisis around the corner — and doubts about whether the economy is resilient enough to cope with a new disruption, such as the impact of automation. "We are at a major watershed. The traditional crisis is finished, maybe. But now the big challenge is technology," says Dario Gallina, of Turin's industrialists association, who warns that the next government will be forced to address the issue. "It could kick many companies out of the market — and in a country like Italy where manufacturing is very strong we have to be careful," he says.

A few miles away in Chieri, however, all Mr Sciarretta sees around him is a desire for a radical rethink at the election. "I feel what people say in here, 30 per cent won't vote, and that's a fact. And then the majority is either Five Star or Lega [Northern League], maybe some Berlusconi, that's the game," he says. "For me, it's hard to say. What we need is a dictatorship for 10 years."

2.1%
European Commission forecast for Italy's budget deficit in 2017. It is predicted to be 1.8% in 2018

1.5%
Growth in Italy's gross domestic product in 2017 — below the eurozone average of 2.4 per cent

10.8%
Official unemployment rate in December 2017. Joblessness peaked at 13 per cent in late 2014

Speed read

Populist surge According to the polls, populist parties could help form the next Italian government

What recovery? Many voters believe business leaders and politicians are operating in a parallel universe

Fiscal blowout Economists believe the new government will try to boost growth by raising the budget deficit

Whirlpool relocation Factory closure fuels discontent with EU

On a grey late winter morning on the outskirts of Chieri, east of Turin, Monica Brizzolesi, who works in logistics at a Whirlpool plant that makes compressors for fridges, is lamenting her fate.

Next month, she and 496 other colleagues are set to lose their jobs, after Embraco, the Brazilian unit of the US appliance maker, announced that it would shift production to Slovakia. "I have an economics degree but it's hard to find another job in this area,

globalisation has destroyed everything," she says. "Maybe one could dream of working at an Amazon warehouse for €900 a month, or doing pizza delivery on a bicycle, but if that's the future of Italy, we are in bad shape."

Ms Brizzolesi calls the EU "useless" yet still plans to vote for the pro-European centre-left in the election, because "populism is the worst thing". But many of her fellow protesters at the factory will be backing the anti-establishment Five Star Movement. "Mine is not a vote of protest, I am voting for their platform," says Gianni Trudu. "Five Star has detached themselves from the party system of right and left — and if you cut ties to the caste you can do a lot more."

The Whirlpool crisis was the last thing the centre-left government needed on the eve of the election. Economic development minister Carlo Calenda took the workers' side, even describing the executives as "riff-raff". He visited Brussels to discuss whether state aid rules could be waived to help the company, and to debate what he described as the "social dumping" based on lower wages and lower taxes that drove the relocation.

But he rejects the idea of protectionism: "Multinationals give work to 1.25m people in Italy. Whoever wants them out of Italy is crazy. What we need is to seriously tackle the problem of relocations."


The planned lay-off of hundreds of Whirlpool factory workers has angered voters in the Turin area




Northern League as misguided efforts that were imposed by Brussels.

Populist gains in the election could also affect Rome's position on trade, which in the past few years has been remarkably willing to embrace EU trade deals with Canada and Japan, specifically, and open trade more generally.

GDP growth in OECD countries



Italy's public debt problem



Sources: Based on OECD and European Commission data

COMPANIES

Cabby's tip put Comcast chief on to Sky deal

Murdochs under pressure to increase offer for broadcaster's shares in order to complete sale of Fox assets to Disney

MATTHEW GARRAHAN AND
ARASH MASSOUDI — LONDON

The London cab driver asked by an American passenger what he thought of the UK pay-television market could not have known that his answer might potentially sway a set of takeover deals worth tens of billions of dollars.

But back in November, Brian Roberts, Comcast's chief executive, asked his driver for his opinion. "[He] was incredibly knowledgeable about the differences between Virgin and Sky," he said. After taking the cab to a shopping centre, where he saw a demonstration of Sky's latest set-top box, Mr Roberts was "terribly impressed".

Mr Roberts subsequently identified Sky as his company's most logical target. Three months later, he has stunned media watchers with a \$22.1bn proposal to buy the pan-European broadcaster.

The deal sketched out by Comcast — it has not yet made a formal offer — is the latest twist in a reshaping of the global media industry, pitting Mr Roberts, the son of Comcast founder Ralph Roberts, against the Murdoch family and the might of Walt Disney, the world's largest media company.

The Murdochs control 21st Century Fox and have agreed to sell its entertainment assets — including its 39 per cent stake in Sky — to Walt Disney in a deal worth \$66bn including debt. Separately, Fox is trying to buy the shares in Sky that it does not own in a deal worth £11.7bn, or £10.75 a share, valuing Sky at £18.5bn.

Before Comcast's intervention, Sky seemed to be destined to become part of Fox and then Disney. Analysts believe the UK government will eventually approve Fox's offer after it agrees to

'Comcast has a history of buying companies to build our company'

Brian Roberts, chief executive

implement several remedies, such as ringfencing Sky News to prevent the Murdoch family exerting any influence over it. Government approval would then clear the way for Disney to add Sky to the assets it is buying from Fox, including its cable channels, Hollywood movie studio and Star of India.

But the £12.50-a-share all-cash Comcast deal, pitched at a significant premium to the Fox offer, is likely to appeal to the independent Sky shareholders that own about 60 per cent of the company — and raises the prospect of a counterbid from Fox and Disney.

The first communication Comcast made with Sky's leadership came early yesterday when Mr Roberts phoned Jeremy Darroch, Sky chief executive, and Martin Gilbert, Sky's deputy chairman. Comcast's pitch in the coming weeks will be geared towards Sky's independent directors: this has turned the spotlight to Mr Gilbert, who the Murdochs courted only 14 months ago — and who eventually recommended shareholders accept the Fox offer of £10.75 a share.


Sky said in a statement that it noted the possible all-cash offer and advised shareholders to take no action because

On the radar




Will Disney/Fox make the next move?

Significant Comcast deals, value (\$bn)



Comcast puts Disney's avenue to 100m Fox viewers under threat

Users (m)



Profile

Dealmaker pitted against old sparring partners

The softly spoken Brian Roberts, pictured, does not come across as an all-conquering dealmaker but in the past 20 years he has been involved in several landmark media deals.

As a keen squash player who won gold at the Maccabiah Games — also known as the Jewish Olympics — Mr Roberts, below, knows about the rigours of competition.



In 2001, he led the \$50bn merger of Comcast with AT&T Broadband in a deal that laid the foundations for the company's fastest growing business — internet provision.

A decade later, Comcast snapped up NBC Universal in a deal that eventually valued the broadcaster at about \$30bn.

Not all of his big moves have come off. A \$54bn bid for Walt Disney in 2004 that looked to marry Comcast's distribution with Disney's content was rejected by Disney.

Comcast also came close to buying rival Time Warner Cable in 2014 with an all-share deal worth \$42.5bn, but withdrew the offer in the face of mounting regulatory opposition.

His interest in Sky pits him against old sparring partners — Rupert Murdoch and his sons at Fox, and Bob Iger at Disney. He will know that the competition will be intense.

no firm offer had yet been made. Disney declined to comment on Comcast's proposal for Sky but analysts believe it is likely to respond.

"I think Disney will ask Fox to offer more for Sky and then Disney will absorb that cost," says Michael Nathanson, an analyst with MoffettNathanson.

Under the guidelines for UK takeovers, Fox and Disney cannot attempt to buy shares of Sky in the market to try to build up enough of a shareholding to block a deal by Comcast. One of the few options available if they want to secure Sky is to table a higher offer than Fox's current proposal. This bid would probably need to be more than the £12.50 offer from Comcast.

It is unclear how much Disney and Fox would need to offer — or whether Comcast is ready for a bidding war.

Analysts say Sky is worth more since its success in securing rights to Premier League football for another three years — mainly because it is paying significantly less for the packages. Analysts had expected the cost of the rights to increase by £300m a year but it is falling by £200m. "That's £500m [a year] lower than originally thought," says Citi

analyst Thomas Singlehurst. "Every £100m of costs less than consensus forecast adds 5p to earnings. The standalone Sky valuation in our view is about £13 a share when you factor in the savings from the Premier League."

Mr Roberts told the Financial Times that Sky would be a good fit for Comcast, pointing to its record in acquiring companies and investing in them. Universal Studios, NBC Universal's theme park unit, now generates more annual cash flow than its parent company did at the time Comcast bought it in 2011.

The NBC broadcast network now leads its peers after trailing rival networks before it was owned by Comcast.

"Comcast has a history of buying companies to build our company," he adds, referring to the long history of acquisition started by his late father in 1963, when he and his partners acquired a cable television operation in Tupelo, Mississippi with 1,200 subscribers.

Mr Roberts and his colleagues have big plans for Sky but will have to wait for Disney and Fox to respond before they know whether they will be able to put those plans into action.

See Lex

Technology

Apple to set up staff medical centres

TIM BRADSHAW — LOS ANGELES

Apple is preparing to launch a network of clinics for staff and their families, in what might be a way to test its broader ambitions in healthcare.

Tim Cook, chief executive, recently described the healthcare industry as an area where the company might make a "meaningful impact", but the iPhone maker has been typically secretive about its plans.

The discovery of a website for an organisation called the AC Wellness Network provides a hint that Apple's ambitions extend beyond digital health devices such as its Watch.

AC Wellness describes itself as an "independent medical practice dedicated to delivering compassionate, effective healthcare to the Apple employee population", launching in spring 2018.

Job advertisements on recruitment sites describe AC Wellness as a "subsidiary of Apple", operating in the Santa Clara area that surrounds the iPhone maker's Cupertino headquarters.

"AC Wellness Network believes having trusting, accessible relationships with our patients, enabled by technology, promotes high-quality care and a unique patient experience," its website says. "The centres offer a unique con-

cierge-like healthcare experience for employees and their dependants."

According to records from the internet Archive, the domain name acwellness.com was bought, presumably by Apple, in the second half of last year.

News of AC Wellness was first reported by CNBC.

Apple did not immediately respond to a request for further comment on its plans or the website.

Apple's apparent move into medical services follows Amazon's plan to part-



Tim Cook sees healthcare as a sector where Apple can make an impact

ner Berkshire Hathaway and JPMorgan Chase to create a new not-for-profit healthcare company to try to lower healthcare costs for their collective 1m employees.

The trio's intention to extend the new company's services to "potentially all Americans" wiped tens of billions of dollars from the market cap of traditional healthcare companies such as Walgreens Boots Alliance last month.

While the scope of Apple's health centre initiative is still unclear, the most valuable company has been making slow but steady inroads into the health market for several years.

After the launch of Apple Watch in 2014, it has used its HealthKit and ResearchKit software and data platforms to connect its users' health information across third-party apps and into clinical research projects.

Apple is working with Stanford University on a study to see if the Watch's sensors can detect heart abnormalities. With a forthcoming software update, iPhone owners will be able to download their electronic medical records from some US hospitals.

At Apple's annual meeting this month, Mr Cook was critical of the US healthcare and insurance system, saying it "doesn't always motivate the best innovative products".

In association with

TALKING ABOUT MY GENERATION

How is the great intergenerational wealth transfer affecting your family finances?

Rosie Carr
Deputy Editor,
Investors Chronicle

Charlotte Ransom
Chief Executive Officer,
Netwealth

Jonathan Eley
Deputy Editor, *FT Lex*,
Financial Times

19 March 2018 | London

Over the next twenty years, an estimated \$4tn will pass from one generation to the next in the UK and USA. Join FT Money's Editor, **Claer Barrett** to discuss how to manage your family finances and investments.

For more information or to register, please visit:
live.ft.com/MyGeneration

An event from **FINANCIAL TIMES LIVE**

COMPANIES

Financials

Rothschild prepares for dynastic change of guard

Chairman's son set to take reins as the Franco-British bank starts to diversify

HANNAH MURPHY — LONDON

David de Rothschild is stepping aside as chairman of Rothschild this summer to pass the reins to his son Alexandre in a long-awaited changing of the guard at the Franco-British investment bank.

The younger Mr de Rothschild has long been groomed to succeed his father as the seventh generation of the banking dynasty that was founded 200 years ago. Currently executive deputy chairman, he joined the bank in 2008 after stints in both investment banking and private equity at Bank of America and Bear Stearns.

The dynastic handover, expected to take place in June, comes amid a push by the investment bank to diversify from its core French and British advisory business to help it ride out less buoyant periods in Europe's mergers and acquisitions market.

Since joining the bank, Alexandre de Rothschild, 37, has set up and helped oversee the private equity business. The group has also been increasingly investing in its small US operations and last year completed its first sizeable acquisition to expand its private bank.

David de Rothschild, who was born in New York, oversaw the merger of the then-separate French and UK banks in 2012 in a combination designed to unify two branches of the Rothschild family and bolster the balance sheet. Before that, the 75-year-old had been running the UK part of the bank after Evelyn de Rothschild, his cousin, retired in 2004.

The overhaul of the corporate structure was an

opportunity for Mr de Rothschild to put in motion a succession plan by bringing his third child and only son to the supervisory board. It also allowed the family to tighten control over the group by buying out minority shareholders.

Still, his tenure has occasionally been dogged by family infighting among offshoots of the financial dynasty that sit outside the unified group.

Today, the family has 58 per cent of voting rights and owns a 49 per cent stake in the company. Just over 26 per cent of the group's shares are listed on Paris's Euronext exchange.

Rothschild's latest half-year results, published in November, showed revenue from its global advisory business, which accounts for about three-fifths of revenues, fell 8 per cent to €492m. By contrast, its private wealth and asset management and merchant banking divisions each posted growth of more than 30 per cent in the six months to September.

Overall, revenues rose 6 per cent year on year to €852m and pre-tax profit increased 10 per cent to €206m.

Despite the dip in advisory revenue, the bank remained steady in fifth position by EU M&A revenue in 2017 as with the previous year, taking a 6 per cent share of the market, according to Dealogic.


Rothschild's shares, which were hit dramatically in the wake of the financial crisis, have gained more than 15 per cent since the beginning of 2017. The bank boasts Emmanuel Macron, the French president, as a former employee. Mr Macron became known as the "Mozart of finance" for his role at Rothschild in advising Nestlé on its \$12bn acquisition of a Pfizer unit in 2012.

See Lex



Top banks for European dealmaking

M&A net revenue (\$m)



Source: Dealogic

Waiting in the wings: Alexandre de Rothschild will this summer take over from his father David, inset, as chairman of Rothschild – the seventh generation of the banking dynasty founded 200 years ago

Balint Pornecz/Bloomberg

Automobiles

California gives green light to allow fully driverless cars

TIM BRADSHAW — LOS ANGELES

California has approved broad new rules allowing driverless cars that do not require a human operator to sit behind the wheel, in a long-awaited win for Silicon Valley lobbyists.

The state's Department of Motor Vehicles has been given the green light to allow car manufacturers and tech companies to test and deploy autonomous vehicles without a "natural person" inside the car.

Until now, a human had always been present to take over in the event of emergency, a requirement that pushed some Silicon Valley companies to start testing outside their home state.

"This is a major step forward for autonomous technology in California," said Jean Shiimoto, director of the California DMV.

However, some safety campaigners argue it could turn California's roads into a potentially lethal "video game".

The new rules – approved on Monday – have been in development for more than three years and have been eagerly anticipated by Silicon Valley, where the law has often been seen as holding back technological innovation. Fifty companies, including Alphabet, Uber, Apple, GM, Ford and Toyota are already testing self-driving cars in California.

If manufacturers can show the DMV that their technology is safe and resilient to cyber attacks, local residents could be taking rides in driverless vehicles within a few months. The DMV can start issuing the permits from April 2, even as proposed federal rules governing autonomous vehicles remain stalled in Washington.

For the first time in Silicon Valley neighbourhoods, vehicle designers will be able to deploy cars without a steering wheel, brake or accelerator pedal, as long as they can demonstrate compliance with safety standards.

That marks a change to the DMV's original proposals from 2015, and is a concession that tech companies have

long demanded. Waymo, formerly Google's self-driving car project, has argued it will be safer for passengers and other road users to rely only on computers and sensors than to allow a human driver to take hold of manual controls.

For now, humans will not be taken out of the system altogether. Robot cars will require constant supervision and any vehicle without a human driver must have a "remote operator" that can take over using a wireless connection or talk to the car's occupants.

Companies must also provide a "law enforcement interaction plan" explaining how they will respond if their car is pulled over by the police, even if empty.

Proponents of autonomous driving say computers are better drivers than people. But John Simpson of Consumer Watchdog said using a remote operator

'[Using a remote operator] will be just like playing a video game, except lives will be at stake'

"will be just like playing a video game, except lives will be at stake".

California is not the first state to permit completely self-driving vehicles. In October, Waymo started testing cars without a driver in Phoenix, Arizona, and plans to launch a commercial service there this year. Nevada and Michigan have also allowed fully driverless vehicles, while other states have run pilots.

The development in California is significant because it leads the country in terms of the number of companies testing autonomous cars on its highways, ranging from global car manufacturers to small Silicon Valley start-ups.

Mr Simpson of Consumer Watchdog said Californian drivers anxious about sharing a road with robot cars should keep a close eye on the "disengagement reports" that manufacturers must submit every year. At the most recent count, Waymo's autonomous driving system disengaged – meaning a human had to step in – once every 5,596 miles. General Motors' Cruise division had a disengagement every 1,254 miles.

A day after California's new rules were approved, Ford announced that it was looking to the other side of the US for its next autonomous test.

The automaker is working with food delivery services Domino's and Postmates in Miami, Florida, to investigate how ordinary people respond to receiving their pizza or groceries via self-driving car. Ford ran a similar pilot in Ann Arbor, Michigan last year and has been part of the Californian testing programme since 2015.



Ford is among groups already testing self-driving cars in California

FINANCIAL TIMES
WISHES YOU A PROSPEROUS
YEAR OF THE DOG



EXCLUSIVE
NEW YEAR OFFER

*Try all that the FT offers for 4 weeks for a special low price


Start your trial today at ft.com/cny

- ▶ Free delivery of the newspaper to your home or office
- ▶ Our unique insight, comment and analysis to keep you informed
- ▶ FT Weekend - our award-winning mix of global news, culture and lifestyle journalism
- ▶ Full Premium digital access to FT.com and our mobile app

*After the 4-week trial, you will be enrolled automatically in an annual contract which is billed quarterly. You may cancel your 4-week trial at any time. Subscriptions are non-refundable. Offer open to individual customers based in Asia-Pacific and expires on 05/03/2018. Trials are only allowed to be used once.



FINANCIAL
TIMES



THE FINANCIAL TIMES GREAT DEBATES

North Korea is a threat to world peace

Who is more dangerous, "Little Rocket Man" Kim Jong Un or "Mentally Deranged Dotard" Donald Trump? Is the North Korean leader crazy or rational? Is Pyongyang the biggest threat to world peace or could the American president be the one pushing the region and the world towards nuclear Armageddon?

Join Jamil Anderlini, Asia Editor, and six of the FT's leading journalists as they debate this vexing issue.

Participants:

Peter Spiegel, *News Editor*
David Pilling, *Africa Editor*
Pilita Clark, *Business Columnist*
Leslie Hook, *San Francisco Correspondent*
Tom Mitchell, *Beijing Bureau Chief*
Bryan Harris, *Seoul Bureau Chief*
Jamil Anderlini, *Asia Editor*

Venue:

Mettā, 21/F California Tower,
30-32 D'Aguilar St, Central,
Hong Kong

Date:

Tuesday, 20th March, 2018

Time:

6.30pm

Ticket price:

HK\$480

Registration from 6.30pm; debate from 7.00pm onwards.
Tickets can be purchased at www.eventbrite.com

MARKET DATA

FT500: THE WORLD'S LARGEST COMPANIES

Table with 10 columns: Stock, Price, Day Chg, High, Low, Yld, P/E, MCap. Lists major companies from Australia, Europe, Asia, and the US.

FT 500: TOP 20

Table with 5 columns: Stock, Close price, Prev price, Day change, Week change, Month change. Lists top 20 FT 500 companies.

FT 500: BOTTOM 20

Table with 5 columns: Stock, Close price, Prev price, Day change, Week change, Month change. Lists bottom 20 FT 500 companies.

BONDS: HIGH YIELD & EMERGING MARKET

Table with columns: Issuer, Red, Date, Coupon, Ratings, Bid price, Bid yield, Mth's spread, Day's change, US\$.

BONDS: GLOBAL INVESTMENT GRADE

Table with columns: Issuer, Red, Date, Coupon, Ratings, Bid price, Bid yield, Mth's spread, Day's change, US\$.

INTEREST RATES: OFFICIAL

Table with columns: Country, Rate, Current, Since, Last, Mth Ago, Year Ago.

INTEREST RATES: MARKET

Table with columns: Instrument, Over, Under, Change, One month, Three months, Six months, One year.

COMMODITIES

Table with columns: Energy, Price, Change, Agricultural & Cattle Futures, Price, Change.

PRECIOUS METALS (PM LONDON FX)

Table with columns: Metal, Price, Change, Month, Year.

BOND INDICES

Table with columns: Index, Day's change, Month's change, Year change, Return 1 month, Return 1 year.

BONDS: INDEX-LINKED

Table with columns: Index, Price, Yield, Prev, Month return, Value, Market, No of stocks.

BONDS: TEN YEAR GUV SPREADS

Table with columns: Country, Bid vs Spread, Yield, Bid vs Spread, Yield, Bid vs Spread.

VOLATILITY INDICES

Table with columns: Index, Feb 27, Day Chng, Prev, 52 wk high, 52 wk low.

BONDS: BENCHMARK GOVERNMENT

Table with columns: Country, Red, Date, Coupon, Bid, Bid yield, Day's change, Mth's spread, US\$.

GLTCS: UK CASH MARKET

Table with columns: Term, Price, Red, Day, Week, 52 Week, Emnt.

GLTCS: UK FTSE ACTUARIES INDICES

Table with columns: Index, Price, Red, Day, Week, 52 Week, Emnt.

MANAGEMENT SERVICE advertisement for FT.com/funds, featuring a large FT logo and promotional text.

FINANCIAL TIMES advertisement for Tradeweb, featuring the FT logo and Tradeweb branding.

FT Health

The Future of Rare Diseases

Wednesday February 28 2018

www.ft.com/reports | @ftreports

Niche drugs market looks set to balloon

Genetics Treatments are being tailored to a specific mutation, writes *Andrew Jack*

In just a few years, rare diseases have moved from neglected "orphan" status into the mainstream of drug development, with a growing number of pharmaceutical companies acquiring and investing in life-saving treatments that benefit targeted groups of patients.

Now they are converging with the broader trend of "personalised medicine" that is transforming research, outcomes and the economics of the industry more widely. "We're moving from blockbusters to niche-busters," says Hilary Thomas, chief medical adviser at KPMG.

Many thousands of orphan conditions affecting small numbers of patients with unusual conditions remain poorly researched with few medical options for treatment and poor prognoses.

However, a growing number – from Gaucher's disease, which can cause an enlarged spleen and liver as well as skeletal disorders, to cystic fibrosis, which affects mainly the lungs – have potent treatments that were inconceivable until recently.

That is reflected in growing corporate investment. In January, Sanofi paid nearly \$12bn for Bioverativ, a US company focused on haemophilia and other rare blood conditions. Shire, which acquired Baxalta for \$32bn in 2016 to strengthen its rare disease portfolio, has been subject to fresh speculation that it will itself be bought after a previous thwarted takeover bid by AbbVie.

EvaluatePharma, a research group, estimates total orphan drug sales will rise from \$127bn for 2017 to \$217bn in 2022, while their share of the revenue from all prescription medicines will increase from 16 per cent to 21 per cent.

Orphan treatments were long viewed as pioneers in personalised medicines, focused on conditions with a single mechanism and transformative, *Continued on page 2*

Discovery will aid fight against the horrifying birth defect caused by Zika



Breakthrough: a team led by Brazilian scientist Mayana Zatz has found that only babies with a genetic predisposition are born with microcephaly after infection with the Zika virus. Page 3 — Hilaera Media/Dado Galdieri for Financial Times

Inside

Termeer: the founding father of orphan drugs

Pioneer helped show niche markets could be a route to profits

Page 2

'Waiting for death'

Many of China's rare disease sufferers cannot afford treatment

Page 3

Fight against leprosy is far from over

Action needed as more than 200,000 new cases are diagnosed each year

Page 4

Genome project offers hope to many patients

Identifying genes could mean an end to the 'diagnostic odyssey' that some sufferers have faced

Page 4



And so we dare

In the fight against rare disease, where there's a will, there's always a way.

Rare disease patients often face a multi-year journey just to get to a diagnosis. They deserve a better way. And we are answering the call.

Champion the fight against rare disease with us at shirepharmaceuticals.co.uk

hope

care

admire

support

persevere

carry on

persist

commit

go further

promise

FT Health The Future of Rare Diseases

Mayana Zatz Her work on twins shows a genetic component to the birth defect, says *Andres Schipani*

Brazilian team finds clue to congenital Zika syndrome

Soon after the Zika epidemic broke out in Brazil, Mayana Zatz — an acclaimed geneticist who, for the preceding four decades had been tracking rare genetic disorders that destroy muscles — received a surprise phone call from the scientific director of a research foundation in São Paulo.

Carlos de Brito Cruz told her Brazil was in a crisis and asked if she could contribute in any way.

It was 2015, and scientists were trying to establish a link between the Zika virus — usually a mild condition that can cause flu-like symptoms — and a horrifying birth defect called microcephaly in which babies are born with abnormally small heads. The affected children also face a lifetime of mental disabilities, seizures, as well as hearing and sight problems.

Prof Zatz's first thought was: "I am not an infectologist, I have nothing to do with this."

Over the years, she and her team at the Human Genome Research Centre had helped close to 30,000 patients, after identifying genes responsible for muscular dystrophies, mainly neuromuscular.

"But [after hearing more about the birth defects] this caught my eye right away because only a small percentage was suffering from it." She immediately began to wonder whether there was a genetic component to the condition, so she rounded up her team and started looking for twins in Brazil's worst-affected areas.

"What interests us very much is what protects some people from the effects of mutation," says Prof Zatz, a larger-than-life 70-year-old, who has won accolades for her work as a scientist (see box).

Despite her scientific achievements, this new assignment was very different to the work she had been doing before. "This was completely out of her scope of action, she has never worked specifically with virology, but her acumen on this was incredible," says Ernesto da Silva, a biological engineer who is a member of her team in the Zika project.

The scientists identified Brazilian twins whose mother had been exposed to the Zika virus. Two pairs were identical and the rest were non-identical.

The identical twins all had microcephaly, but of the seven other pairs of non-identical twins, only one pair of twins was both affected.

The remaining six pairs were "discordant", with only one child presenting with microcephaly, even though they had shared the same uterine environment.

"She got that stuck into her head, called us and said: 'Let's design a project, I think there is something there,'" Mr da Silva says.

Prof Zatz and her team went to Recife and interviewed and examined the families and twins, with particular interest in the patients she called *discordantes* or anomalous — that had one twin affected while the other was not.

To identify any possible genetic component, her team compared all the gene sequences from eight pairs of twins and 10 other babies that developed the Zika syndrome.

"They found that between 6 and 12 per cent of the babies born from mothers infected with the Zika virus had what Prof Zatz calls "congenital Zika syndrome".

"[Even] if the baby has these genetic susceptibility factors, we believe the baby will not have microcephaly unless



Mystery: Mayana Zatz (bottom right) tested non-identical twins where only one of the pair had the Zika birth defect (above left, top) — Hileea Media/Dado Galderisi for Financial Times



CV Mayana Zatz

BORN

July 16, 1947, Tel Aviv, Israel. She moved with her family to Paris the following year and arrived in São Paulo in 1955.

EDUCATION

Bachelors in biology and PhD in human and medical genetics at University of São Paulo, post-doctoral research in medical genetics at UCLA.

TO STAY OR GO

She had several offers to stay on and work in the US, but decided to return to Brazil where she felt she could "make a difference".

She returned to São Paulo to focus on the diseases that cause muscular dystrophy: "Nobody worked on that here then," she says. She went on to pioneer the use of molecular biology in Brazil's fight against rare diseases.



CAREER HIGHLIGHTS

1982 — 1992
Assistant professor of human and medical genetics, University of São Paulo
1992 — present
Professor of human and medical genetics, University

of São Paulo
2000 — present
Director of the Human Genome and Stem-Cell Research Centre (Hug-Cell), University of São Paulo
1996 — present
Member of the Brazilian Academy of Sciences
2005 — present
Member of The World Academy of Sciences (TWAS), a Trieste-based institution that fosters science in developing countries
1981 — 2015
Founder and president of the Brazilian Muscular Dystrophy Association (ABDIM)
2010 — 2012
Board of revisers (BORE) for Science, the scientific journal

INTERESTS

Her interests include jogging, travelling, watching films and going to the theatre.

the baby is infected by the Zika virus," Prof Zatz explains.

The results, published in Nature earlier this month, confirm the hypothesis of a genetic influence on susceptibility to the congenital Zika syndrome and microcephaly, she says.

More than that, it suggests that there could be a value in taking this line of research with other diseases.

"This [work] shows that genetics and infectious diseases can have an intersection," Prof Katz says.

"We could identify the people with the genetic alteration and prioritise them in a future vaccine strategy. Same with mothers who are pregnant and have exposure to Zika, if they don't have this gene, they do not have to worry," says Prof Zatz, who has

two children and has two grandchildren.

Since the outbreak, Zika has receded as people build up resistance to infection and authorities have been fighting the Aedes aegypti mosquitoes that spread the virus.

Brazil declared an end to its Zika emergency in May last year after recording a 95 per cent fall in the

number of cases in the first four months of 2017 compared to the previous year. However, the virus remains a health threat in the region and a return could affect future generations.

The World Health Organization announced last year that 31 countries had reported microcephaly cases, or central nervous system malformations, potentially linked to Zika.

Chinese rare disease patients 'waiting for death'

Costs

Recent moves by Beijing could open the door to wider coverage, say *Tom Hancock* and *Wang Xueqiao*

Li Wenyan was unable to afford medical bills for her seven-month-old daughter's rare disease, which could cause her heart to fail within months. So she turned to a new source of funding: asking strangers for money on the internet.

"I come from generations of peasants and my family has an annual income of Rmb30,000 [\$4,730]," Ms Li wrote in a post on a crowdfunding site. She added that treatment costs were Rmb120,000 a month and with "debts piled high I have no other option," alongside two emojis showing hands clasped in prayer.

The campaign attracted more than 1,800 donations, raising almost Rmb30,000 — enough for one course of treatment with the drug Myozyme, manufactured by French company Sanofi.

But with thousands of other people vying for money on the platform, the final amount fell short of her Rmb300,000 target. "The second round of fundraising did not come in time," Ms Li said.

Ms Li's daughter, Yuxin, was nine months old when she died of Pompe disease, a genetic disorder which causes sugar molecules to build up in muscle tissue including the heart.

China has the world's largest population of people with rare diseases — numbering between 15m and 20m according to estimates. China has rolled out state medical insurance for some drugs over the past decade but the vast majority of orphan drugs are not included. Even when they are, there is no guarantee that regional insurers will cover them. Myozyme, a treatment for Pompe, was approved for use in China in 2015 but

Ms Li was unable to gain any state reimbursement for the drug.

People trying to pay for a treatment for a rare disease in China face bills that are on average three times their annual individual incomes and nearly two times higher than their household incomes, according to a survey of rare disease sufferers carried out in 2015.

There are about 35,000 Pompe patients in China, according to an association representing sufferers. About 80 per cent of them are adults who face annual medical costs of around Rmb5m compared with annual average incomes in China of about Rmb70,000 a year. It is impossible for sufferers in most parts of China to obtain government insurance contributions for Pompe drugs.

Ji Chongzhe, of Jilin province in the north-east, says his child developed Pompe symptoms at seven months, but local doctors initially thought it was a cold. Only after a genetic test at a hospital in Beijing was the disease identified. Eight hospital stays later, Mr Ji says he has spent his life savings — over Rmb100,000 — on treatment. He earns just Rmb4,000 a month. "After the New Year holiday we will sell our house, but that will only keep us going for half a year. After that if there's still no medical coverage, we can only wait for death."

Medhat El-Bialy, head of rare diseases in emerging markets at Sanofi, admits

'Solving the payment problem in China is much tougher than solving the approvals problem'

limited insurance is a key barrier to access. With only 38 per cent of orphan drugs available in the US on the market in China "there is catching up to do," he says.

Wang Cheng's four-year-old daughter suffers from Gaucher's disease, a rare



Expensive burden: there is scant health coverage for diseases such as epidermolysis bullosa (above) — Shanghai Butterfly Centre

genetic disorder that can cause a build-up of fatty substances in certain organs. He estimates that of the approximately 400 people in the country with the condition, 138 have received help from charity programmes while at least 100 patients have no access to medicine at all. Efforts to treat the disease severely strain charity budgets. Treating just six Gaucher's disease patients in Shanghai costs the Shanghai Rare Disease Prevention and Treatment Fund about Rmb2m a month, according to its chairman Li Dingguo.

Access to healthcare can also depend on residency. Zhou Yingchun's family has just paid Rmb300,000 for a bone-marrow transplant for their 15-year-old daughter who suffers from epidermolysis bullosa — a condition which causes the skin to blister and tear. As the operation was performed outside the family's official place of residence, the family had to pay the entire cost themselves.

Huang Rufang, founder of the Chinese Organisation for Rare Disorders, says wider government insurance was the most urgent need for rare disease patients. "Overall the provincial insurers do not do a good job," he says.

But recent moves by policymakers give some hope. Beijing last year announced it would draw up its first official list of rare diseases which could open the door for wider cost support.

Some wealthier provinces have already added rare disease drugs to their reimbursement lists, he adds, while the China Food and Drug Administration, the top pharmaceutical administrator, has vowed to speed up the process for approving new treatments. "I think the CFDA's measures have encouraged drug developers," Mr Huang says.

The drug administrator's move "creates an opportunity for Pfizer and for other companies to bring innovative



drugs to Chinese patients," says Krishna Padmanabhan head of rare disease marketing in China for the US company, describing a "huge unmet medical need" in the country.

Chinese companies are also spotting the opportunities. Beijing-based start-up Prosit Sole Biotechnology is developing a treatment for norovirus gastroenteritis in immunocompromised patients, a market it estimates could be worth \$500m per year in the US although only half of that amount in China.

Healthcare How it works in China

Basic healthcare coverage was free for Chinese citizens until the 1980s, after which state-run hospitals began to charge for treatments. China began rolling out universal state-subsidised health insurance around a decade ago. Contributions are means-tested, meaning lower earners pay less. Now, 95 per cent of the population is covered by schemes under which the state will fund part of the cost of medical treatment, compared with 30 per cent in 2012.

However, while state medical coverage in China is broad, it remains shallow. Apart from a few hundred drugs deemed essential, the only treatments eligible for state co-payment are those named on a national drug reimbursement list, which was updated last year to include about 2,500 drugs.

Many life-saving drugs, including most used to treat rare diseases, are not on this list — and their prices are set by manufacturers following the abolition of official price caps for most drugs in 2015.

Provinces determine the level at which most drugs on the national list are reimbursed, depending on their resources. As a result, the proportion of costs paid by the state can be as low as 30 per cent. Patients generally pay a larger proportion of their medical bills in China's poorest provinces and in the countryside, even though incomes are also generally lower.

A rare disease charity in China says the typical annual cost of Myozyme, which is used to treat Pompe disease, is Rmb2m (\$315,000). Most provinces will not contribute towards the cost of the drug, which means patients or their families will have to fund the entire cost themselves.

Tom Hancock and Wang Xueqiao

